Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
$9.86
+4.7%
$8.58
$0.23
$8.36
$38.89M2.79602,475 shs47,225 shs
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
$4.33
+6.3%
$3.88
$1.46
$12.15
$35.99M0.2642,443 shs10,661 shs
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
$2.26
+0.4%
$3.89
$1.79
$5.18
$34.98M0.32561,526 shs100,581 shs
Mannatech, Incorporated stock logo
MTEX
Mannatech
$4.80
+2.8%
$5.95
$4.28
$12.45
$9.26M0.6114,527 shs3,492 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
-2.18%+7.41%-14.29%+96.66%+294.80%
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
-7.71%-7.71%+7.11%+21.13%+177.82%
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
-5.06%+0.45%-32.43%-37.50%-25.50%
Mannatech, Incorporated stock logo
MTEX
Mannatech
-4.30%+6.62%-25.16%-36.81%-54.04%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
$9.86
+4.7%
$8.58
$0.23
$8.36
$38.89M2.79602,475 shs47,225 shs
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
$4.33
+6.3%
$3.88
$1.46
$12.15
$35.99M0.2642,443 shs10,661 shs
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
$2.26
+0.4%
$3.89
$1.79
$5.18
$34.98M0.32561,526 shs100,581 shs
Mannatech, Incorporated stock logo
MTEX
Mannatech
$4.80
+2.8%
$5.95
$4.28
$12.45
$9.26M0.6114,527 shs3,492 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
-2.18%+7.41%-14.29%+96.66%+294.80%
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
-7.71%-7.71%+7.11%+21.13%+177.82%
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
-5.06%+0.45%-32.43%-37.50%-25.50%
Mannatech, Incorporated stock logo
MTEX
Mannatech
-4.30%+6.62%-25.16%-36.81%-54.04%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
1.00
Sell$4.00-59.43% Downside
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
2.67
Moderate Buy$11.00154.34% Upside
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
2.00
Hold$6.00165.49% Upside
Mannatech, Incorporated stock logo
MTEX
Mannatech
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest MTEX, ATHA, EVAX, and GRCE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/24/2026
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
Set Price Target$4.00
4/24/2026
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
Lower Price TargetBuy$12.00 ➝ $8.00
4/24/2026
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
Reiterated RatingBuy$16.00
4/21/2026
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
Reiterated RatingSell (D-)
3/10/2026
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
Initiated CoverageBuy$10.00
3/9/2026
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
Lower Price TargetBuy$11.00 ➝ $9.00
3/9/2026
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
Reiterated RatingBuy$16.00
2/19/2026
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
Initiated CoverageBuy$10.00
(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
N/AN/AN/AN/A$11.60 per shareN/A
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
$7.53M4.79N/AN/A$2.04 per share2.12
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
N/AN/AN/AN/A$4.86 per shareN/A
Mannatech, Incorporated stock logo
MTEX
Mannatech
$108.04M0.09N/AN/A($2.75) per share-1.75
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
-$96.94M-$9.68N/AN/AN/AN/A-107.06%-89.89%N/A
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
-$7.71M-$1.32N/A0.79N/AN/A-61.43%-29.14%N/A
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
-$9.57M-$0.40N/AN/AN/AN/A-15.58%-14.51%6/22/2026 (Estimated)
Mannatech, Incorporated stock logo
MTEX
Mannatech
-$15.21M-$8.00N/AN/AN/A-14.08%-398.35%-45.63%5/11/2026 (Estimated)

Latest MTEX, ATHA, EVAX, and GRCE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/15/2026Q4 2025
Mannatech, Incorporated stock logo
MTEX
Mannatech
N/A-$5.94N/A-$5.94N/A$26.64 million
2/12/2026Q3 2026
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
-$0.09-$0.14-$0.05-$0.14N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
N/AN/AN/AN/AN/A
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
N/AN/AN/AN/AN/A
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
N/AN/AN/AN/AN/A
Mannatech, Incorporated stock logo
MTEX
Mannatech
$0.204.17%-100.00%N/A N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
N/A
9.70
9.70
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
0.41
5.85
5.85
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
N/A
14.96
14.96
Mannatech, Incorporated stock logo
MTEX
Mannatech
0.48
1.10
0.56

Institutional Ownership

CompanyInstitutional Ownership
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
57.12%
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
11.04%
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
6.08%
Mannatech, Incorporated stock logo
MTEX
Mannatech
12.98%

Insider Ownership

CompanyInsider Ownership
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
19.80%
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
41.64%
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
11.10%
Mannatech, Incorporated stock logo
MTEX
Mannatech
41.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
403.94 million3.16 millionNo Data
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
608.34 million4.87 millionNo Data
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
N/A15.47 million13.76 millionN/A
Mannatech, Incorporated stock logo
MTEX
Mannatech
2501.93 million1.13 millionNot Optionable

Recent News About These Companies

Mannatech, Incorporated
Mannatech Announces Notification of Late Filing
Mannatech Reports Financial Results for Third Quarter 2025
Mannatech Extends Loan Repayment to March 2027
Mannatech, Incorporated (MTEX) - Yahoo Finance
Mannatech appoints Peter Griscom COO

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Athira Pharma stock logo

Athira Pharma NASDAQ:ATHA

$9.86 +0.44 (+4.67%)
As of 05/7/2026

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Evaxion A/S stock logo

Evaxion A/S NASDAQ:EVAX

$4.32 +0.26 (+6.27%)
As of 11:18 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Grace Therapeutics stock logo

Grace Therapeutics NASDAQ:GRCE

$2.26 +0.01 (+0.44%)
As of 11:18 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.

Mannatech stock logo

Mannatech NASDAQ:MTEX

$4.80 +0.13 (+2.78%)
As of 10:45 AM Eastern

Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.